Antituberculosis medications

24,855views

Antituberculosis medications

before placement

before placement

Acyanotic congenital heart defects: Pathology review
Cyanotic congenital heart defects: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Coronary artery disease: Pathology review
Peripheral artery disease: Pathology review
Valvular heart disease: Pathology review
Cardiomyopathies: Pathology review
Heart failure: Pathology review
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Aortic dissections and aneurysms: Pathology review
Pericardial disease: Pathology review
Endocarditis: Pathology review
Hypertension: Pathology review
Shock: Pathology review
Vasculitis: Pathology review
Cardiac and vascular tumors: Pathology review
Dyslipidemias: Pathology review
Adrenal insufficiency: Pathology review
Adrenal masses: Pathology review
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Thyroid nodules and thyroid cancer: Pathology review
Parathyroid disorders and calcium imbalance: Pathology review
Diabetes mellitus: Pathology review
Cushing syndrome and Cushing disease: Pathology review
Pituitary tumors: Pathology review
Hypopituitarism: Pathology review
Diabetes insipidus and SIADH: Pathology review
Multiple endocrine neoplasia: Pathology review
Congenital gastrointestinal disorders: Pathology review
Esophageal disorders: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Malabsorption syndromes: Pathology review
Diverticular disease: Pathology review
Appendicitis: Pathology review
Gastrointestinal bleeding: Pathology review
Colorectal polyps and cancer: Pathology review
Pancreatitis: Pathology review
Gallbladder disorders: Pathology review
Jaundice: Pathology review
Viral hepatitis: Pathology review
Cirrhosis: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Pigmentation skin disorders: Pathology review
Acneiform skin disorders: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Skin cancer: Pathology review
Back pain: Pathology review
Rheumatoid arthritis and osteoarthritis: Pathology review
Seronegative and septic arthritis: Pathology review
Gout and pseudogout: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Scleroderma: Pathology review
Sjogren syndrome: Pathology review
Bone disorders: Pathology review
Bone tumors: Pathology review
Myalgias and myositis: Pathology review
Neuromuscular junction disorders: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Congenital neurological disorders: Pathology review
Headaches: Pathology review
Seizures: Pathology review
Cerebral vascular disease: Pathology review
Traumatic brain injury: Pathology review
Spinal cord disorders: Pathology review
Dementia: Pathology review
Central nervous system infections: Pathology review
Movement disorders: Pathology review
Demyelinating disorders: Pathology review
Adult brain tumors: Pathology review
Pediatric brain tumors: Pathology review
Neurocutaneous disorders: Pathology review
Congenital renal disorders: Pathology review
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Acid-base disturbances: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Urinary incontinence: Pathology review
Urinary tract infections: Pathology review
Kidney stones: Pathology review
Renal and urinary tract masses: Pathology review
Disorders of sex chromosomes: Pathology review
Prostate disorders and cancer: Pathology review
Testicular tumors: Pathology review
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Benign breast conditions: Pathology review
Breast cancer: Pathology review
Complications during pregnancy: Pathology review
Congenital TORCH infections: Pathology review
Choanal atresia
Laryngomalacia
Allergic rhinitis
Nasal polyps
Upper respiratory tract infection
Sinusitis
Laryngitis
Retropharyngeal and peritonsillar abscesses
Bacterial epiglottitis
Nasopharyngeal carcinoma
Respiratory distress syndrome: Pathology review
Cystic fibrosis: Pathology review
Pneumonia: Pathology review
Tuberculosis: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Obstructive lung diseases: Pathology review
Restrictive lung diseases: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Valvular heart disease: Clinical
Infective endocarditis: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Hypothyroidism and thyroiditis: Clinical
Thyroid nodules and thyroid cancer: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal insufficiency: Clinical
Adrenal masses and tumors: Clinical
MEN syndromes: Clinical
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Peptic ulcers and stomach cancer: Clinical
Gastroparesis: Clinical
Diarrhea: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Colorectal cancer: Clinical
Diverticular disease: Clinical
Anal conditions: Clinical
Gastrointestinal bleeding: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Jaundice: Clinical
Viral hepatitis: Clinical
Cirrhosis: Clinical
Immunodeficiencies: Clinical
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Anemia: Clinical
Leukemia: Clinical
Thrombocytopenia: Clinical
Lymphoma: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Thrombophilia: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Pneumonia: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Cystic fibrosis: Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Antihistamines for allergies
Glucocorticoids
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Loop diuretics
Antiplatelet medications
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Osmotic diuretics
Carbonic anhydrase inhibitors
Potassium sparing diuretics
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications

Transcript

Watch video only

Antituberculosis medications are agents used to treat tuberculosis, a disease caused by the bacteria Mycobacterium tuberculosis.

Mycobacteria are an interesting bunch, they’re slender, rod-shaped, and need oxygen to survive, in other words, they’re “strict aerobes.”

They’ve got an unusually waxy cell wall, which is mainly a result of the production of mycolic acid.

This waxy cell wall makes them incredibly hardy, and allows them to resist weak disinfectants and survive on dry surfaces for months at a time.

Antituberculosis medications act mainly by preventing the production of mycolic acid and the synthesis of this cell wall.

Although about two billion people worldwide are infected with tuberculosis, or simply ‘TB, the vast majority, about 90-95%, don’t develop symptoms. And this is because usually the immune system can contain it.

So Mycobacterium tuberculosis is usually transmitted via inhalation, which is how they gain entry into the lungs.

TB can avoid the mucus traps and make its way to the deep airways and alveoli where we have macrophages which eat up foreign cells, digest, and destroy them.

With TB, they recognize foreign proteins on their cell surface, and phagocytize them, or essentially package them into a space called a phagosome.

With most cases, the macrophage then fuses the phagosome with a lysosome, which has hydrolytic enzymes that can pretty much break down any biochemical molecule.

TB’s tricky though, and once inside the macrophage, they produce a protein that inhibits this fusion, which allows the mycobacterium to survive.

It doesn’t just survive, though, it proliferates, and creates a localized infection.

Three weeks after initial infection, cell-mediated immunity kicks in, and immune cells surround the site of TB infection, creating a granuloma.

The tissue inside the middle dies as a result, a process referred to as caseous necrosis. This area is known as a “Ghon focus”.

In some cases, the mycobacteria is killed off by the immune system, and that’s the end of that.

In other cases, even though they were walled off, they remain viable, and are therefore still alive, but they’re just dormant. This stage of the disease is called latent TB.

When a person’s immune system becomes compromised, like with AIDS or with aging, the Ghon focus can be reactivated.

T cells quickly release cytokines to try and control the new outbreak, which forms more areas of caseous necrosis.

This time though, it tends to cavitate, or form cavities, which can allow the bacteria to disseminate.

The bacteria can cause bronchopneumonia; but it can also spread via the vascular system and infect almost every other tissue in the body, called systemic miliary TB.

Fortunately, there are many medications that can treat tuberculosis and they are often used together, in case the bacteria is resistant to one or more of the drugs.

Let’s start with isoniazid. It can be used on its own to treat latent infections and as prophylaxis for people traveling to regions where tuberculosis is common.

Isoniazid can be administered orally or parenterally.

In order to work, it’s first converted by a mycobacterial enzyme called peroxidase, into its active metabolite, iproniazid.

A mutation in the gene that codes for this enzyme helps the bacteria develop resistance, because the mutated enzyme won’t activate the medication.

Iproniazid inactivates enzymes associated with mycolic acid synthesis, and mycolic acid is needed to build bacterial cell walls.

It also inhibits mycobacterial peroxidase, preventing the bacteria from metabolizing hydrogen peroxide, which accumulates inside the cell causing serious damage.

Side effects include rash, fever, and systemic lupus erythematosus, called drug-induced SLE.

It can also cause vitamin B6 deficiency, which leads to anemia and neurological symptoms like dizziness, ataxia, or encephalopathy, but the most common is peripheral neuropathy.

Fortunately, these side effects can be prevented with the administration of pyridoxine, or vitamin B6.

Pyridoxine is also useful as an antidote in case of overdose with isoniazid, which can cause seizures, anion gap metabolic acidosis, and coma.

Last, but not least, patients who receive isoniazid should be assessed monthly for symptoms of hepatitis and jaundice in order to detect this serious potential side effect.

If liver damage is present, the medication should be discontinued right away.

Rifampin is the next medication. It can be administered orally or parenterally and acts by inhibiting mycobacterial RNA polymerase, and therefore, the synthesis of RNA.

A mutation in the gene that codes for this enzyme helps the bacteria develop resistance.

Since rifampin gets widely distributed throughout the body, it can get into urine, saliva, tears, feces and sweat, which turns them orange!

But, the most important side effect is hepatitis, which is more severe at high doses.

Luckily, it’s pretty uncommon, but elderly or alcoholic patients, or those who already have liver disease, are at higher risk.

Rifampin also causes other side effects such as rash, fever, and gastrointestinal symptoms like abdominal pain, diarrhea, nausea, and vomiting.

Now, an important fact is that rifampin is a strong CYP450 enzyme inducer, which means it increases the metabolism of many medications, like ritonavir and other HIV antivirals.

This can be problematic since these people with HIV are at a higher risk of developing active tuberculosis.

Key Takeaways

Anti-tuberculosis (TB) medications are drugs used to treat tuberculosis. Common TB medications include Isoniazid (INH), Rifampin (RIF) Pyrazinamide (PZA), and Ethambutol (EMB). Other TB drugs include Streptomycin, Capreomycin, Amikacin, and Levofloxacin. TB drugs are typically administered in combination, which helps minimize resistance to one of the drugs.

Side effects of TB drugs include vitamin B6 deficiency for isoniazid. This is prevented by taking isoniazid with vitamin B6 supplements (pyridoxine). Other side effects include hepatotoxicity for isoniazid, ethambutol, and pyrazinamide; and thrombocytopenia and neutropenia for Rifampin.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Treatment of Latent Tuberculosis Infection" Annals of Internal Medicine (2017)
  5. "Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis" Cold Spring Harbor Perspectives in Medicine (2015)
  6. "Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis" Journal of Biological Chemistry (2018)
  7. "WHO consolidated guidelines on tuberculosis. Module 4" World Health Organization (2020)